DOJ Sheds Light on Evaluation of Corporate Compliance Policies
Client Alert | less than 1 min read | 02.24.17
On February 8, 2017, DOJ Fraud Section issued new guidance on the Evaluation of Corporate Compliance Programs. This guidance, discussed more fully in our blog, serves as a useful framework for compliance professionals in crafting and strengthening corporate compliance policies, corporate officers and directors who want to ensure their compliance program meets the DOJ’s expectations, and counsel to use in navigating communications and disclosures to the DOJ Fraud Section.
Contacts
Insights
Client Alert | 3 min read | 01.21.26
Atlantic Biologicals Opioid DPA: DOJ Continues Ramp Up of Criminal Corporate Healthcare Enforcement
On January 13, 2026, Miami-based pharmaceutical wholesaler Atlantic Biologicals Corporation entered into a two-year DPA, admitting to conspiracy to distribute and dispense controlled substances, including more than 14 million opioid doses to “pill mill” pharmacies in Texas at a markup. The DOJ and DEA underscored the company’s deliberate evasion of compliance checks and disregard for red flags signaling diversion.
Client Alert | 3 min read | 01.21.26
FedRAMP Proposes Updates to Authorization Process—Six New RFCs Released for Public Comment
Client Alert | 3 min read | 01.20.26
DoW Joins SBA’s Fight Against Alleged Pass-Through Fraud in the 8(a) Program
Client Alert | 3 min read | 01.20.26
Federal Government Challenges Minnesota Law Requiring Affirmative Action in State Government
